pharmaphorum Podcast

A philosophical look at market turn in the Age of AI, with John Holodnak

28 Apr 2026

Contributed by Lukas

Today, the life sciences sector is prioritising recruitment of leaders who can scale efficiently in capital-constrained environments, as well as focus...

Providing patient access to new therapies, with Dean Erhardt

22 Apr 2026

Contributed by Lukas

Pharma and tech companies are working more closely together than ever. As proven by the news of Merck and NVidia’s new partnership, for example. But...

Pushing through barriers to commercial launch success, with Amanjeet Singh Saluja

16 Apr 2026

Contributed by Lukas

Despite billions spent on new technology and improving data analytics, companies continue to struggle with commercial launch success, with around 35% ...

Every drug is a story, with Thomas Goetz

14 Apr 2026

Contributed by Lukas

Here at pharmaphorum we tend to focus on the latest developments in the pharmaceutical space. And to be fair, that’s quite a lot to keep us busy. Bu...

Looking to gene therapy for ocular diseases, with Lance Baldo

08 Apr 2026

Contributed by Lukas

In a new episode of the pharmaphorum podcast, web editor Nicole Raleigh spoke with Lance Baldo, CEO of Beacon Therapeutics, a clinical-stage biotechno...

Creating what nature has not from AI and computational molecular biophysics with Kashif Sadiq

31 Mar 2026

Contributed by Lukas

In a new episode of the pharmaphorum podcast, recorded at BIO-Europe Spring in Lisbon, Portugal, web editor Nicole Raleigh spoke with Kashif Sadiq, fo...

On collaboration, computational chemistry, and cutting-edge AI – with Olga Nissan

25 Mar 2026

Contributed by Lukas

At BIO-Europe Spring 2026 in Lisbon, Portugal, web editor Nicole Raleigh spoke with Dr Olga Nissan, vice president of business development at Evogene,...

Making AI work where it matters, with Rob DiCicco

17 Mar 2026

Contributed by Lukas

In a new pharmaphorum podcast, web editor Nicole Raleigh was joined by Rob DiCicco, vice president of portfolio management at Transcelerate Biopharma ...

Treating genetic disease at scale with tRNA, with Michelle Werner

10 Mar 2026

Contributed by Lukas

Genetic diseases are notoriously challenging to treat, especially when each condition requires a tailored approach. With over 10,000 known genetic dis...

AI in clinical development & ‘white space’, with Andrew McKinnon

03 Mar 2026

Contributed by Lukas

In a new episode of the pharmaphorum podcast, web editor Nicole Raleigh speaks with Andrew McKinnon, senior vice president and executive general manag...

Collaboration & personalisation in rare disease R&D, with AOP Health’s Melissa Fellner

26 Feb 2026

Contributed by Lukas

For 30 years, the AOP Health Group has been dedicated to developing innovative solutions to address unmet medical needs, particularly in the fields of...

Policy in Focus: Unpacking GLOBE, GUARD, and TrumpRx with Alice Valder Curran

24 Feb 2026

Contributed by Lukas

Slowly but surely – and just in time for the State of the Union – the full picture of the Trump Administration’s Most-Favoured Nations drug pric...

On JPM2026 and healthcare investment today, with Jonah Comstock

17 Feb 2026

Contributed by Lukas

Following his return from San Francisco and the JP Morgan Healthcare conference last month, editor-in-chief Jonah Comstock sat down with pharmaphorum ...

On addressing drug waste and ensuring access, with Jeff Harper

10 Feb 2026

Contributed by Lukas

The rising cost of drugs in 2025 was driven by several factors, including inflation, supply chain issues, and the demand for specialty drugs – strai...

From Buzzword to Strategy: Reverba Global Talks Omnichannel Engagement on the pharmaphorum Podcast

05 Feb 2026

Contributed by Lukas

The term "omnichannel engagement" has become embedded in today’s healthcare conversations. Yet the biopharmaceutical industry often approaches it su...

On quality data for quality learnings, with Lisa Sims

03 Feb 2026

Contributed by Lukas

Outdated training and behaviours impact patient outcomes and can lead to patient risk. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks...

JPM2026: Broadening AI drug discovery to include the lab, with Yann Gaston-Mathe

27 Jan 2026

Contributed by Lukas

At the JP Morgan Healthcare conference this year, a lot of the discourse around AI drug discovery focused on making the leap from purely in silico dru...

On AI and equity in the cancer setting, with Mohit Manrao

20 Jan 2026

Contributed by Lukas

The global impact of digital transformation in the last few decades cannot be understated. And now, of course, artificial intelligence (or AI) is maki...

JPM2026: AI diagnostics and translational research, with Andrew Beck

15 Jan 2026

Contributed by Lukas

On-site on the sidelines of JP Morgan Healthcare conference in San Francisco this year, pharmaphorum editor-in-chief Jonah Comstock sat down with Andr...

Shaping the future of immunodeficiency care, with Dr Jörg Schüttrumpf

06 Jan 2026

Contributed by Lukas

An increasing prevalence of immunodeficiency and autoimmune disorders has led to increasing demand for plasma-derived immunoglobulin therapies and a n...

Aligning with national efforts to modernise cancer diagnostics, with Andrew Newland

30 Dec 2025

Contributed by Lukas

A liquid biopsy is a blood test that detects signs of cancerous tumors, including tumour cells and cancer cell DNA. In a new pharmaphorum podcast, web...

Rethinking prescription drug affordability, with Vinay Patel

29 Dec 2025

Contributed by Lukas

It goes without saying that drug pricing and accessibility in the United States are complex indeed. In a new pharmaphorum podcast, web editor Nicole R...

An AI supercomputer and discovering next-gen brain disorder treatments, with Tarek Samad

23 Dec 2025

Contributed by Lukas

Gefion is Denmark’s first AI supercomputer, named after a goddess in Danish mythology. It is operated by the Danish Centre for AI Innovation (DCAI),...

On genomics, NGS, and doing much more good than bad, with Markus Vossman

22 Dec 2025

Contributed by Lukas

Illumina innovative sequencing and array technologies are fuelling groundbreaking advancements in life sciences research, translational and consumer g...

Delivering the right behavioural ingredients for the moment, with Amy Bucher

19 Dec 2025

Contributed by Lukas

The FDA recently announced that it will begin offering faster drug reviews to certain medicines, reducing the drug review process from approximately t...

AI for the planet, AI for life sciences – with Patrick Leung

18 Dec 2025

Contributed by Lukas

In a new pharmaphorum podcast, guest Patrick Leung – chief technology officer at Faro Health – discusses how AI can transform clinical trials. The...

On the future of AI in life sciences, with women at the helm

17 Dec 2025

Contributed by Lukas

The Women in AI Healthcare event series - hosted by Real Chemistry in collaboration with Pharma Brands – brings together dynamic female leaders to d...

On AI and computational support of biochemistry, with Alan Roth

16 Dec 2025

Contributed by Lukas

AI’s growing influence in pharma is transforming traditional drug discovery timelines. In a new pharmaphorum podcast, web editor Nicole Raleigh spea...

Harnessing the cell's own degradation machinery, with Benedict Cross

15 Dec 2025

Contributed by Lukas

AI and computational small molecule drug discovery approaches are helping to realise the potential of targeted protein degradation (TPD) in molecular ...

How blood tests can inform cancer treatment decisions, with Craig Eagle

12 Dec 2025

Contributed by Lukas

Blood is a rich source for biomarker development, and CTCs are increasingly proving themselves to be valuable in cancer prognosis and treatment predic...

The NHS, system burden, and a transformation prescription, with Ruth Chambers

11 Dec 2025

Contributed by Lukas

There is a world of difference between the NHS from its beginnings in 1948 and the NHS as it is now. In a new pharmaphorum podcast, web editor Nicole ...

On CB1s as an alternative to GLP-1s, with Punit Dhillon

10 Dec 2025

Contributed by Lukas

CB1 inhibition is an approach that taps into the body’s natural metabolism to burn fat while preserving muscle for more sustainable weight loss. Unl...

Digital transformation as a third lever in the affordability debate, with Alfred Olivares

09 Dec 2025

Contributed by Lukas

Technology and AI can help healthcare systems tackle the affordability challenge while ensuring patients still benefit from cutting-edge treatments. I...

Towards a democratic era of medicine, with Simon Kohl

08 Dec 2025

Contributed by Lukas

There are many efforts at the moment to transform the expensive, labour intensive, and high failure rate processes of drug discovery into automated dr...

CDMOs: Their crucial role and how to select one, with Sigma Mostafa

05 Dec 2025

Contributed by Lukas

A CDMO plays a crucial role in the pharmaceutical and biotechnology industries by providing comprehensive drug development and manufacturing services,...

On US drug shortages and compounding pharmacies, with Shawn Hodges

04 Dec 2025

Contributed by Lukas

Drug shortages are a critical issue in the US, leaving patients and healthcare providers struggling. Compounding pharmacies, however, can curb drug sh...

Delving into the physics of cancer, with Lew Bender

03 Dec 2025

Contributed by Lukas

Intra-tumourally injected therapeutics represent a novel approach to cancer cell death, with high tumour dispersion and cell penetration properties. T...

On inflammation, heart health, and GLP-1 possibilities, with Sandeep Kulkarni

02 Dec 2025

Contributed by Lukas

There is a growing body of evidence on the role of inflammation in predicting heart health. In a new pharmaphorum podcast, web editor Nicole Raleigh s...

On digital twins in rare disease research, with Piet van der Graaf

28 Nov 2025

Contributed by Lukas

With over 7,000 rare diseases affecting an estimated 30 million people in the US alone, these conditions have long been underfunded and under-research...

The hot topics of digitisation, with Rob Verheul

25 Nov 2025

Contributed by Lukas

Graphite Digital’s study of 100 senior pharma leaders across Europe and North America earlier this year investigated organisations’ attitudes towa...

Ten years of innovation at Frontiers Health – Live from Berlin with Jessica DaMassa

19 Nov 2025

Contributed by Lukas

Last week in Berlin the Frontiers Health Conference celebrated its 10th Anniversary with a whirlwind two days of panels and presentations from founder...

Working together to innovate on pragmatic clinical trials, with Rob DiCicco

18 Nov 2025

Contributed by Lukas

Process innovation in the pharmaceutical industry is never easy, but its best chance of success comes when companies come together to work on big prob...

Policy in Focus: Trump’s MFN deals, FDA vouchers, and the government shutdown

07 Nov 2025

Contributed by Lukas

At the end of September, President Trump invited Pfizer CEO Albert Bourla to the Oval Office to announce that the company and the administration had r...

Biotech’s biggest challenge isn’t scientific, but political – with James Roosevelt Jr

04 Nov 2025

Contributed by Lukas

Amid historic advances in cell-based therapies and precision medicine, biotech’s biggest challenge isn’t scientific, it’s political. In a new ph...

On targeted radiotherapeutics, with Marc Hedrick

30 Oct 2025

Contributed by Lukas

Radiation has for over a century been considered one of the most powerful methods of destroying cancer. But, even now, ways to deliver significant dos...

Towards one, cohesive AI workflow: In conversation with Ilya Burkov

28 Oct 2025

Contributed by Lukas

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Ilya Burkov, global head of healthcare & life sciences at Nebius, a company b...

Collaborating on a connected platform journey, with Alexander Alex and Florian Schnappauf

21 Oct 2025

Contributed by Lukas

Bayer and Veeva have partnered for several years across commercial, R&D, and quality functions. But recently Bayer migrated to Veeva’s Vault CRM...

ESMO25: Patient-centric oncological futures with Boehringer Ingelheim

19 Oct 2025

Contributed by Lukas

As pharmaphorum reported during ESMO 2025, fresh from a return to oncology with the FDA approval of zongertinib as a treatment for HER2-positive non-s...

Smoothing a contract pathway through uncertainty: In conversation with Neal Masia

16 Oct 2025

Contributed by Lukas

Back in June, pharmaphorum spoke with Entity Risk’s CEO and co-founder, Neal Masia, a leading health economist, about the unknowns unfolding in the ...

FH25: On the future of health, with Frontiers Health Chairman Roberto Ascione

14 Oct 2025

Contributed by Lukas

In the final episode of our special Frontiers Health limited series of the pharmaphorum podcast, web editor Nicole Raleigh speaks with the Chairman of...

Allosteric small molecule therapies in PD, with Gene Mack

09 Oct 2025

Contributed by Lukas

As Gain Therapeutics announces positive Phase 1b results for its lead compound, GT-02287, pharmaphorum looks back to a conversation with the company’...

FH25: Jessica DaMassa on hosting, hype, and health innovation

08 Oct 2025

Contributed by Lukas

As one of Frontiers Health’s most recognisable faces (and voices), Jessica DaMassa, founder of WTF Health and long-time emcee of the conference, has...

Improving ROI on AI investments and data quality, with Dr Jay Anders

07 Oct 2025

Contributed by Lukas

Healthcare organisations are facing the simultaneous pressures of demonstrating ROI on AI investments, addressing clinician burnout, and satisfying co...

The importance of being disruption ready, with Brandon Pence

03 Oct 2025

Contributed by Lukas

The cell culture media industry is currently experiencing significant growth, driven by the increasing demand for biopharmaceuticals, advancements in ...

FH25: Commercialising Health Tech and Deeptech, with Pilar Fernández Hermida

01 Oct 2025

Contributed by Lukas

This year marks the 10th anniversary of Frontiers Health. In another episode of our limited Frontiers Health series of the pharmaphorum podcast, we sp...

Agentic AI, culture shifts, and commercialisation today: Anthony Cilento post-Axtria Ignite 2025

30 Sep 2025

Contributed by Lukas

In a new pharmaphorum podcast, web editor Nicole Raleigh spoke with Anthony Cilento, vice president, data science & customer insights, at Bayer, i...

FH25: On patient access and equity, with Roberta Sarno

29 Sep 2025

Contributed by Lukas

This year marks the 10th anniversary of Frontiers Health. In another episode of our limited Frontiers Health series of the pharmaphorum podcast, we sp...

FH25: On healthcare innovation with Gary Monk

24 Sep 2025

Contributed by Lukas

This year marks the 10th anniversary of Frontiers Health. In another episode of our limited Frontiers Health series of the pharmaphorum podcast, we sp...

FH25: The art of connection at Frontiers Health with Aline Noizet

19 Sep 2025

Contributed by Lukas

Frontiers Health marks its 10th anniversary this year, celebrating a decade of innovation, collaboration, and the connections that drive progress.   ...

Policy in Focus: Trump’s Most Favoured Nations drug pricing scheme – with Alice Valder Curran

18 Sep 2025

Contributed by Lukas

In Donald Trump's first presidential term, he spoke a lot about "Most Favoured Nations" pricing for pharmaceuticals - that is, bringing the prices tha...

FH25: Exploring the intersection of patients, HCPs, and technology with Denise Silber

17 Sep 2025

Contributed by Lukas

Frontiers Health is back, and celebrating 10 years of innovation, conversation, and collaboration.   In this episode of our Frontiers Health limite...

Doing good in people’s lives: Amy Burroughs discusses CML

11 Sep 2025

Contributed by Lukas

Chronic myeloid leukaemia (CML) is a unique disorder in the rare disease sector because there are multiple approved therapies for patients and, in the...

FH25: Individual centric investing with Steve Seuntjens

10 Sep 2025

Contributed by Lukas

In this episode of our Frontiers Health limited series of the pharmaphorum podcast, Deep Dive editor Eloise McLennan speaks with Steve Seuntjens, Pa...

Pharma and health advertising: Brian Coane on the necessity of humour

09 Sep 2025

Contributed by Lukas

When it comes to breaking down barriers, humour is vitally important, helping to do away with stigma when it comes – in particular – to pharma and...

The glimmer of opportunity behind the storm: Ali Pashazadeh talks biotech investment

05 Sep 2025

Contributed by Lukas

Biotech finance has encountered what can arguably be termed the worst perfect storm in its history, and private investment in biopharma is in the mids...

FH25: The intersection of tech, science & design with Unity Stoakes

03 Sep 2025

Contributed by Lukas

This year marks the 10th anniversary of Frontiers Health. In this episode of our Frontiers Health limited series of the pharmaphorum podcast, web e...

Changing the drug development treatment paradigm: Hilary Eaton on AI and LLMs

02 Sep 2025

Contributed by Lukas

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Hilary Eaton, a rare disease advocate and chief business officer at Profluent abo...

Increasing trial efficiency: Adityo Prakash talks small datasets, real-world scenarios, and organoids

28 Aug 2025

Contributed by Lukas

Characterising the behaviour of drugs in humans has historically required extensive clinical trials at considerable time and cost. So, any lab-derived...

FH25: Ten years at the forefront of health innovation, with Kristin Milburn

27 Aug 2025

Contributed by Lukas

This November marks a major milestone for health innovation as Frontiers Health celebrates its 10th anniversary.   To mark the occasion, pharmaphoru...

MAPs, EAPs, and patient access: Suzanne Aitken on the challenges for pharma

21 Aug 2025

Contributed by Lukas

Managed Access Programs (or MAPs) enable mechanisms for patients with unmet medical needs to get access to new medications outside of the clinical tri...

Weighing in on GLP-1 drugs

19 Aug 2025

Contributed by Lukas

When it comes to GLP-1 drugs like Ozempic, Wegovy, and Mounjaro there’s a lot to talk about, from the science behind the drugs and where it could go...

The TechBio way: Brendan Frey talks genomics, AI, and RNA

14 Aug 2025

Contributed by Lukas

Overall, the pharmaceutical industry is moving away from an approach where AI is task-driven, narrowly focused on a single, isolated problem. Instead,...

Advancing the frontier of cancer diagnostics: Post-ASCO with Eric Matthews

12 Aug 2025

Contributed by Lukas

Caris Life Sciences was founded in 2008 with a simple but powerful purpose – to realise the potential of precision medicine and help improve the liv...

Compliance baked into the design core: On AI in life sciences with Florian Schnappauf

07 Aug 2025

Contributed by Lukas

When it comes to artificial intelligence, the tables are turning and there is a shift in considering it a hype to understanding that AI is a real nece...

Putting patients and their families first: Dr Corina Dutcus, post-ASCO 2025

05 Aug 2025

Contributed by Lukas

At ASCO 2025, Eisai presented data from its oncology portfolio, including in hepatocellular carcinoma and endometrial cancer. In a post-Congress conve...

Enhancing anti-tumour activity: A post-ASCO conversation with Dan Schmitt

31 Jul 2025

Contributed by Lukas

Metastatic pancreatic ductal adenocarcinoma (mPDAC) is a highly aggressive, lethal form of pancreatic cancer that accounts for more than 90% of pancre...

Redefining the Future of Melanoma Treatment: Scancell's Bold Step Forward

29 Jul 2025

Contributed by Lukas

Melanoma is the fifth most common cancer in the UK, accounting for around 4% of all new cancer cases. While immunotherapy is a standard treatment for ...

Why Datavant bought Aetion, and what comes next, with Arnaub Chatterjee

24 Jul 2025

Contributed by Lukas

Back in May, health data company Datavant announced its plans to acquire Aetion, creating a formidable player in the real-world data space. Now that t...

Post-ASCO 25: Pamela Tenaerts on CGTs and digital-first long-term follow-up

22 Jul 2025

Contributed by Lukas

When it comes to CGTs, long-term follow-up care is an issue that makes patient access to these novel investigative treatments extremely limited, given...

Immune mediation, B-cell depletion, and female leadership – with Aoife Brennan

17 Jul 2025

Contributed by Lukas

In a new pharmaphorum podcast, Aoife Brennan, CEO of Climb Bio, discusses the treatment of immune-mediated diseases. Climb Bio is a clinical-stage bio...

Ben Sidders on integrating causality in AI for R&D success

15 Jul 2025

Contributed by Lukas

For AI to truly revolutionise drug discovery, it must move beyond pattern recognition and predictive analytics to include causality, which is essentia...

On nuclear medicine and oncology, SHINE technologies

10 Jul 2025

Contributed by Lukas

Radiopharmaceutical therapy has attracted increasing attention in the treatment of refractory diseases that are not sensitive to current therapies, su...

Unicorns, AI, and the future of health: Highlights from HLTH Europe 2025

08 Jul 2025

Contributed by Lukas

The second annual HLTH Europe conference brought together health leaders, start-ups, investors, and developers from across the globe for a mid-year pu...

On patient-centric treatment decisions and the value of quantitative methodologies, in conversation with Marc Buyse

03 Jul 2025

Contributed by Lukas

In today's healthcare landscape, there is a pressing need for quantitative methodologies that include the patients' perspective in any treatment decis...

Maximising value by uniting the digital backbone: On a new Novo Nordisk and Veeva partnership

01 Jul 2025

Contributed by Lukas

At this year’s Veeva R&D and Quality Summit, it was revealed that Novo Nordisk and Veeva have entered into a new partnership for clinical develo...

The changing landscape of drug clinical assessment: Tommy Bramley on the JCA

24 Jun 2025

Contributed by Lukas

The JCA process was passed into law by the European Union in 2022. The Joint Clinical Assessment is a process that will systematically assess all avai...

Precision, speed, impact: Evolving mass spectrometry for medical science

19 Jun 2025

Contributed by Lukas

Originally employed in atomic physics, mass spectrometry is now an indispensable tool in modern science, and importantly medical science. In a new pha...

IMUNON at ASCO 2025: Changing the micro-tumour environment in advanced ovarian cancer

17 Jun 2025

Contributed by Lukas

Onsite at ASCO 2025 in Chicago, web editor Nicole Raleigh sat down with Dr Stacy Lindborg, CEO of IMUNON, to discuss the company’s oral presentation...

Treating primary bone cancer: The potential of listeria-based bioengineered bacterial immunotherapy

13 Jun 2025

Contributed by Lukas

Osteosarcoma is an extremely challenging and often aggressive cancer that has particular treatment challenges due to location, changing genotypes, and...

Servier’s ASCO 2025 Data: Advancing IDH-Mutated Cancer Treatment with Tibsovo & Voranigo

05 Jun 2025

Contributed by Lukas

At ASCO 2025, Servier presented data in the IDH-mutated cancer space. Onsite at McCormick Place in Chicago, pharmaphorum web editor Nicole Raleigh spo...

Where innovation meets collaboration: Live from Manchester’s City labs 4.0

05 Jun 2025

Contributed by Lukas

In healthcare, some of the most meaningful innovations happen when the right people are brought together in the right place. True progress depends on ...

Live from ASCO 2025: Boehringer Ingelheim on unmet needs and oncology innovation

04 Jun 2025

Contributed by Lukas

Boehringer Ingelheim’s data presented at ASCO 2025 reflected the company’s broad pipeline and growing body of evidence supporting innovative thera...

Bringing patients to research centres: Using AI to bring efficiencies forward

31 May 2025

Contributed by Lukas

Trends can be predicted, and trends can unfold. Here, Liz Beatty – co-founder and chief strategy of Inato – speaks to the beginnings of a new era ...

The need for a science-first mindset: The vaccine landscape today

23 May 2025

Contributed by Lukas

As has been widely reported on, immunisation rates, including for flu and RSV, have been falling – at a troubling rate – and diseases like whoopin...

EAPs: Market access outside of the US and Western Europe

19 May 2025

Contributed by Lukas

Early access programmes (EAPs) for novel medicines are an often-misunderstood strategy outside of western markets. In a new pharmaphorum podcast, web ...

The value of a partner, globally and locally

09 May 2025

Contributed by Lukas

With the FDA and EMA releasing their annual reports detailing novel drug approvals in 2024, a new pharmaphorum podcast looks at recent trends related ...

The ins and outs of HEOR – A lever for global health

06 May 2025

Contributed by Lukas

ISPOR 2025, the leading global conference for Health Economics and Outcomes Research (HEOR), takes place 13th-16th May and marks the 30th anniversary ...

Unpacking Trumps executive order on drug pricing with Alice Valder Curran

02 May 2025

Contributed by Lukas

President Donald Trump’s April 15th executive order, “Lowering Drug Prices by Once Again Putting Americans First”, contained a smorgasbord of po...

AI in drug development: The real hurdle is implementation

01 May 2025

Contributed by Lukas

It can take up to 15 years for a new drug to reach the market, and with only 20% of pharmaceutical professionals adopting AI, one thing is clear: inno...

Patients as active consumers of care: AI-driven personalisation in pharma marketing

29 Apr 2025

Contributed by Lukas

Therapy initiation, adherence, and health outcomes are being driven by artificial intelligence (AI)-powered personalisation. Today’s consumers are m...